Solventum (SOLV)
Makes wound-care, surgical, and dental products alongside healthcare workflow software.
Something off on this page? Send us feedback.
Sells wound-care, infection-prevention, surgical, dental, orthodontic, and healthcare workflow products worldwide. MedSurg supplies most sales, while Dental Solutions and Health Information Systems broaden the portfolio; management is pursuing a separation of the software business to concentrate on medical and dental technology.
Develops healthcare products and software through MedSurg, Dental Solutions, and Health Information Systems. MedSurg covers wound care, infection prevention, surgical supplies, IV-site management, sterilization assurance, and patient monitoring. Dental Solutions sells restorative and orthodontic materials; Health Information Systems automates documentation, coding, reimbursement, speech recognition, and analytics.
Serves hospitals, clinics, dental practices, and health systems worldwide, with the United States contributing most sales. Long-term customer relationships and software embedded in provider workflows support retention.
Operates independently after its 2024 spin-off from 3M, while still using some 3M supply, manufacturing, and distribution infrastructure. Medical and dental products require regulatory clearance, and demand depends partly on provider reimbursement. Management is pursuing a separation of Health Information Systems to focus on MedSurg and Dental Solutions.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | Stifel Nicolaus | Target | Target: $90 | Target: $100 |
| Aug 6, 2026 | UBS | Reiterate | Rating: —Target: $95 | Target: $101 |
| Aug 6, 2026 | Mizuho Securities | Target | Target: $100 | Target: $113 |
| Aug 6, 2026 | KeyBanc | Reiterate | Rating: —Target: $93 | Target: $102 |
| Aug 6, 2026 | BTIG | Reiterate | Rating: —Target: $91 | Target: $95 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $403.0M · Total debt $5.29B · Total assets $14.24B · Shareholders' equity $4.80B
- Revenue
- $2.21B
- Operating income
- $181.0M
- Net income
- $92.0M
No dividends on record.
| Institutions | 75.89% | 129.17M shares | |
|---|---|---|---|
| 901 holders · as of Jun 30, 2026 | |||
| Insiders | 0.26% | 440.3K shares | |
| 19 holders · as of Sep 3, 2026 | |||
| Strategic holders | 15.02% | 25.57M shares | |
| 2 holders · as of Aug 18, 2025 | |||
| Other | 8.83% | 15.04M shares | |
| remainder | |||
170.22M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
3M CoStrategic10 percent owner | 15.02% | 25.57M | filed Aug 18, 2025 |
Independent Franchise Partners LLPInstitution | 9.50% | 16.17M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.73% | 9.76M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 5.65% | 9.62M | as of Jun 30, 2026 |
Trian Fund Management, L.P.Institution | 4.84% | 8.24M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 10, 2026 | Amy McBride Wendell | director | +1,475 | $68.03 |
- Smith & Nephew (ADR)
Advanced wound care rival across NPWT, dressings, and bioactives
- BD
OR infection-prevention and surgical-supplies overlap
- Microsoft
Rival in clinical speech, ambient AI notes, and EHR documentation
- Dentsply Sirona
Broad dental overlap in restoratives, prevention, orthodontics, and workflow
- STERIS
Sterility assurance and OR infection-prevention workflow competitor
- UnitedHealth Group
Revenue-cycle and analytics overlap through Optum Insight
- Envista
Broad dental portfolio overlap across consumables, equipment, and orthodontics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Solventum | $89.18 | +0.38% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Smith & Nephew (ADR) | $27.54 | −0.56% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| BD | $183.47 | +1.53% | $49.79B | 54.4 | 13.9 | 2.4 | −9.6% |
| Microsoft | $498.74 | −0.57% | $3.72T | 27.9 | 25.4 | 11.2 | +17.8% |
| Dentsply Sirona | $9.99 | +5.84% | $1.89B | — | 6.8 | 0.5 | −4.1% |
| STERIS | $208.91 | +0.93% | $20.17B | 25.3 | 18.2 | 3.3 | +7.1% |
| UnitedHealth Group | $373.93 | −0.96% | $342.88B | 24.3 | 17.5 | 0.8 | +0.4% |
| Envista | $24.26 | +3.52% | $3.81B | 40.4 | 15.4 | 1.3 | +7.1% |
| Median | 26.6 | 16.5 | 1.8 | +4.6% |